Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

EVGN vs KMDA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KMDA Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

KMDA Overall Winner 6-Pillar Tally: EVGN 0 – 5 KMDA (1 Tie) Matrix Metrics: EVGN 0 – 10 KMDA

As of Nov 17, 2026, Kamada Ltd (KMDA) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EVGN carries a Unified Composite Score of 41.2/100 (SELL) at $0.34 (N/M Forward P/E, -858.2% operating margin), whereas KMDA carries 42.7/100 (HOLD) at $8.16 (14.1x Forward P/E, 15.4% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EVGN vs KMDA
EVGN NASDAQ
Evogene Ltd.
Agricultural Chemicals
$0.34
-13.17% 1D
Market Cap $6.0M
TTM Revenue $1.7M
Forward P/E N/M
Beta / 30D Vol 1.37β · 138% Vol
Unified Composite Score
41.2 / 100 SELL
Tech 25.0 Fund 48.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $0.36 · SMA50: $0.40
KMDA NASDAQ Head-to-Head Winner
Kamada Ltd
Pharmaceutical Preparations
$8.16
+0.62% 1D
Market Cap $468.2M
TTM Revenue $197M
Forward P/E 14.1x
Beta / 30D Vol 0.96β · 50% Vol
Unified Composite Score
42.7 / 100 HOLD
Tech 28.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 56.8 · SMA20: $7.77 · SMA50: $8.04

6-Pillar Scorecard Institutional Category Breakdown (EVGN 0 – 5 KMDA)

Columns: Metric · EVGN · KMDA
1. Valuation Multiples KMDA
Forward P/E N/M 14.1x
Trailing P/E N/M 21.3x
PEG Ratio N/M 0.64x
EV / Revenue N/M 2.4x
2. Growth & Scale KMDA
Revenue Growth (YoY) -60.7% +10.7%
Earnings Growth (YoY) +0.0% +55.6%
TTM Revenue (USD) $1.7M $197M
Market Cap $6.0M $468.2M
3. Profitability & Quality KMDA
Gross Margin -67.6% 41.6%
Operating Margin -858.2% 15.4%
Net Profit Margin 0.0% 12.7%
Return on Equity (ROE) -182.8% 9.3%
4. Balance Sheet & Cash Flow KMDA
Cash Generation (TTM) -$11M $44M EBITDA
Cash Flow Margin N/A 22.5% EBITDA Mgn
Net Cash / Leverage $6.5M Net Cash $4.70 Book/Sh · 9.3% ROE
Dividend Yield None (0.00%) 2.10%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 339.1% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat KMDA
OpEx & R&D Intensity N/A 26.2% of Rev ($52M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EVGN (0) vs KMDA (10)
Institutional Metric EVGN KMDA Criterion Row Edge
Market Capitalization
Scale
$6.0M $468.2M Larger Scale KMDA
Trailing P/E Ratio
Valuation
N/M 21.3x Lower Multiple KMDA
Forward P/E Ratio
Valuation
N/M 14.1x Lower Multiple KMDA
Revenue Growth (YoY)
Growth
-60.7% +10.7% Higher Growth KMDA
Operating Margin (TTM)
Profitability
-858.2% 15.4% Higher Margin KMDA
Net Profit Margin
Profitability
0.0% 12.7% Higher Margin KMDA
Return on Equity (ROE)
Capital Efficiency
-182.8% 9.3% Higher ROE KMDA
52-Week Range Position
Momentum
9% ($0–$1) 57% ($7–$9) Stronger Trend KMDA
Beta / 30D Volatility
Risk Regime
1.37β · 138% Vol 0.96β · 50% Vol Lower Realized Risk KMDA
Unified Institutional Score
Composite Signal
41.2 / 100 (SELL) 42.7 / 100 (HOLD) Higher Composite KMDA
Trailing 12M Revenue (USD)
Operating Scale
$1.7M $197M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-67.6% 41.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.64x PEG · 2.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M ($6.5M Net Cash) $44M EBITDA ($4.70 Book/Sh · 9.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KMDA +14.81 pp
EVGN: -7.58% · KMDA: +7.23%
3M Horizon KMDA +46.82 pp
EVGN: -43.4% · KMDA: +3.42%
6M Horizon KMDA +61.66 pp
EVGN: -54.29% · KMDA: +7.37%
1Y Horizon KMDA +88.63 pp
EVGN: -71.89% · KMDA: +16.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVGN vs KMDA. Trailing 12-month operating profitability (EVGN -858.2% vs KMDA 15.4%) and valuation multiples (EVGN N/M vs KMDA 14.1x Forward P/E) are benchmarked directly in Pillar 4 below.

EVGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.7M
Gross Margin-67.6%
Op. Margin-858.2%
ROE / Fwd P/E-182.8% · N/M
KMDA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$197M
Gross Margin41.6%
Op. Margin15.4%
ROE / Fwd P/E9.3% · 14.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EVGN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EVGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KMDA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 339.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KMDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EVGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.0M market capitalization and -858.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KMDA Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $468.2M market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment 26.2% of Rev ($52M)
90D Engineering Disclosures 0 Published

Investor FAQ EVGN vs KMDA Key Questions & Quantitative Answers

As of Nov 17, 2026, Kamada Ltd (KMDA) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EVGN carries a Unified Composite Score of 41.2/100 (SELL) at $0.34 (N/M Forward P/E, -858.2% operating margin), whereas KMDA carries 42.7/100 (HOLD) at $8.16 (14.1x Forward P/E, 15.4% operating margin). Technically, EVGN sits in a Neutral phase (RSI 47.4, UNCLASSIFIED options structure) and KMDA sits in a Neutral phase (RSI 56.8, UNCLASSIFIED options structure).

KMDA leads the Growth & Scale pillar: EVGN posts -60.7% YoY revenue growth and +0.0% YoY earnings growth on $1.7M TTM revenue (-67.6% gross margin, -858.2% operating margin), compared with KMDA at +10.7% YoY revenue growth and +55.6% YoY earnings growth on $197M TTM revenue (41.6% gross margin, 15.4% operating margin). On trailing 12-month operating scale, EVGN generates $1.7M in USD-normalized revenue versus $197M for KMDA. In operating R&D and SG&A reinvestment, EVGN deploys N/A (0 90-day corporate R&D disclosures) versus 26.2% of Rev ($52M) (0 disclosures) for KMDA.

KMDA screens cheaper on headline valuation multiples. EVGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas KMDA trades at 14.1x Forward P/E, 21.3x Trailing P/E, 0.64x PEG, and 2.4x EV/Revenue (22.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVGN (-182.8% ROE) versus KMDA (9.3% ROE) capital efficiency.

In options market volatility and institutional positioning, EVGN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.37β · 138% Vol realized risk). By comparison, KMDA carries 339.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.96β · 50% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.